These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 21041579)

  • 1. Meta-analysis: age and effectiveness of prophylactic implantable cardioverter-defibrillators.
    Santangeli P; Di Biase L; Dello Russo A; Casella M; Bartoletti S; Santarelli P; Pelargonio G; Natale A
    Ann Intern Med; 2010 Nov; 153(9):592-9. PubMed ID: 21041579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials.
    Ghanbari H; Dalloul G; Hasan R; Daccarett M; Saba S; David S; Machado C
    Arch Intern Med; 2009 Sep; 169(16):1500-6. PubMed ID: 19752408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of implantable cardioverter-defibrillators.
    Sanders GD; Hlatky MA; Owens DK
    N Engl J Med; 2005 Oct; 353(14):1471-80. PubMed ID: 16207849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of age and medical comorbidity on the effectiveness of implantable cardioverter-defibrillators for primary prevention.
    Chan PS; Nallamothu BK; Spertus JA; Masoudi FA; Bartone C; Kereiakes DJ; Chow T
    Circ Cardiovasc Qual Outcomes; 2009 Jan; 2(1):16-24. PubMed ID: 20031808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical therapy versus implantable cardioverter -defibrillator in preventing sudden cardiac death in patients with left ventricular systolic dysfunction and heart failure: a meta-analysis of > 35,000 patients.
    Peck KY; Lim YZ; Hopper I; Krum H
    Int J Cardiol; 2014 May; 173(2):197-203. PubMed ID: 24636548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in patients with left ventricular systolic dysfunction: 14 years after MADIT.
    Franqui-Rivera H; Sotomonte JC
    P R Health Sci J; 2011 Jun; 30(2):78-83. PubMed ID: 21682151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved survival associated with prophylactic implantable defibrillators in elderly patients with prior myocardial infarction and depressed ventricular function: a MADIT-II substudy.
    Huang DT; Sesselberg HW; McNitt S; Noyes K; Andrews ML; Hall WJ; Dick A; Daubert JP; Zareba W; Moss AJ;
    J Cardiovasc Electrophysiol; 2007 Aug; 18(8):833-8. PubMed ID: 17537209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of a microvolt T-wave alternans screening strategy for implantable cardioverter-defibrillator placement in the MADIT-II-eligible population.
    Chan PS; Stein K; Chow T; Fendrick M; Bigger JT; Vijan S
    J Am Coll Cardiol; 2006 Jul; 48(1):112-21. PubMed ID: 16814657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relation of body mass index to sudden cardiac death and the benefit of implantable cardioverter-defibrillator in patients with left ventricular dysfunction after healing of myocardial infarction.
    Choy B; Hansen E; Moss AJ; McNitt S; Zareba W; Goldenberg I;
    Am J Cardiol; 2010 Mar; 105(5):581-6. PubMed ID: 20185000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MADIT II, the Multi-center Autonomic Defibrillator Implantation Trial II stopped early for mortality reduction, has ICD therapy earned its evidence-based credentials?
    Coats AJ
    Int J Cardiol; 2002 Jan; 82(1):1-5. PubMed ID: 11786150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of gender on survival amongst patients with implantable cardioverter defibrillators for primary prevention against sudden cardiac death.
    Henyan NN; White CM; Gillespie EL; Smith K; Coleman CI; Kluger J
    J Intern Med; 2006 Nov; 260(5):467-73. PubMed ID: 17040253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction: a pooled analysis of 10 primary prevention trials.
    Nanthakumar K; Epstein AE; Kay GN; Plumb VJ; Lee DS
    J Am Coll Cardiol; 2004 Dec; 44(11):2166-72. PubMed ID: 15582314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of fragmented QRS in primary prevention implantable cardioverter defibrillator recipients with left ventricular dysfunction.
    Forleo GB; Della Rocca DG; Papavasileiou LP; Panattoni G; Sergi D; Duro L; Mahfouz K; Magliano G; Santini L; Romeo F
    J Cardiovasc Med (Hagerstown); 2011 Nov; 12(11):779-84. PubMed ID: 21941203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of left ventricular ejection fraction and QRS duration on the survival benefit of implantable cardioverter-defibrillators: meta-analysis of primary prevention trials.
    Katritsis DG; Siontis KC; Bigger JT; Kadish AH; Steinman R; Zareba W; Siontis GC; Bardy GH; Ioannidis JP
    Heart Rhythm; 2013 Feb; 10(2):200-6. PubMed ID: 23107652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do implantable cardioverter defibrillators improve survival in patients with chronic kidney disease at high risk of sudden cardiac death? A meta-analysis of observational studies.
    Makki N; Swaminathan PD; Hanmer J; Olshansky B
    Europace; 2014 Jan; 16(1):55-62. PubMed ID: 24058182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implantable cardioverter defibrillators for primary prevention in patients with nonischemic cardiomyopathy: A systematic review and meta-analysis.
    Akel T; Lafferty J
    Cardiovasc Ther; 2017 Jun; 35(3):. PubMed ID: 28129469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of the implantable defibrillator among elderly patients with a history of life-threatening ventricular arrhythmias.
    Healey JS; Hallstrom AP; Kuck KH; Nair G; Schron EP; Roberts RS; Morillo CA; Connolly SJ
    Eur Heart J; 2007 Jul; 28(14):1746-9. PubMed ID: 17283003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of implantable cardioverter defibrillators for primary prevention of sudden cardiac death in subgroups a systematic review.
    Earley A; Persson R; Garlitski AC; Balk EM; Uhlig K
    Ann Intern Med; 2014 Jan; 160(2):111-21. PubMed ID: 24592496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms underlying the lack of effect of implantable cardioverter-defibrillator therapy on mortality in high-risk patients with recent myocardial infarction: insights from the Defibrillation in Acute Myocardial Infarction Trial (DINAMIT).
    Dorian P; Hohnloser SH; Thorpe KE; Roberts RS; Kuck KH; Gent M; Connolly SJ
    Circulation; 2010 Dec; 122(25):2645-52. PubMed ID: 21135366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gender differences in clinical outcome and primary prevention defibrillator benefit in patients with severe left ventricular dysfunction: a systematic review and meta-analysis.
    Santangeli P; Pelargonio G; Dello Russo A; Casella M; Bisceglia C; Bartoletti S; Santarelli P; Di Biase L; Natale A
    Heart Rhythm; 2010 Jul; 7(7):876-82. PubMed ID: 20380893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.